First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian Cancer
Part of paid clinical trials in Sarasota, Florida.
- Sponsor
- Accent Therapeutics
- Study ID
- NCT06799065
- Phase
- PHASE1
- Status
- Recruiting
Conditions
- Advanced Solid Tumors
- Breast Cancer Recurrent
- High-grade Serous Ovarian Carcinoma
- Ovarian Cancer
- Triple Negative Breast Cancer
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- ATX-295 — DRUGATX-295 Tablets will be taken orally
Study Details
The goal of this study is to identify a safe and tolerated dose of the orally administered KIF18A inhibitor ATX-295. In addition, this study will evaluate the pharmacokinetics, pharmacodynamics and preliminary antitumor activity of ATX-295 in patients with advanced solid tumors and ovarian cancer.
Key Dates
- Start date
- Mar 21, 2025
- Status verified
- Feb 2026
- Primary completion
- Apr 30, 2027
- Completion
- Aug 30, 2027
Study Design
- Enrollment
- 90 participants (estimated)
- Allocation
- NON_RANDOMIZED
- Intervention model
- SEQUENTIAL
- Primary purpose
- TREATMENT
Arms
- Experimental: Dose EscalationSubjects will be enrolled at various doses and/or schedules of ATX-295 to identify the expansion dose(s) and RP2D
- Experimental: Dose Expansion: Platinum-Resistant, -Refractory, or -Intolerant HGSOC
Primary Outcome Measure
Recommended phase 2 dose (RP2D) and/or maximum tolerated dose (MTD) of ATX-295 [ Time Frame: 12 months ]
Central Contacts
- Priya Rajaratnam339) 970-7383
Locations (5)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Florida Cancer Specialists | Sarasota | Florida | 34232 | Latisha Hall 941-377-9993 Judy Wang, MD (PRINCIPAL_INVESTIGATOR) |
| SCRI Oncology Partners | Nashville | Tennessee | 37203 | Latisha Hall 615-329-7640 Deepak Bhamidipati, MD (PRINCIPAL_INVESTIGATOR) |
| MD Anderson Cancer Center | Houston | Texas | 77030 | Timothy Yap, MD, PhD (PRINCIPAL_INVESTIGATOR) |
| NEXT Oncology | San Antonio | Texas | 78229 | Ildefonso Ismael Rodriguez Rivera, MD (PRINCIPAL_INVESTIGATOR) |
| NEXT Virginia | Fairfax | Virginia | 22031 | Alexander Spira, MD, PhD, FACP (PRINCIPAL_INVESTIGATOR) |
Find similar trials in Sarasota, FL
By condition
Related Studies
- Use of CA125 and Complementary Biomarkers for the Early Detection of Ovarian Cancer in Low Risk WomenRecruiting · M.D. Anderson Cancer Center · Miami, Florida
- Integrated Cancer Repository for Cancer ResearchRecruiting · University of Nebraska · Greenwood Village, Colorado
- TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage CancerPHASE2 · Recruiting · American Society of Clinical Oncology · Birmingham, Alabama
- SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and RegistryRecruiting · Massive Bio, Inc. · Birmingham, Alabama